What are the symptoms and signs of lung cancer recurrence? Several symptoms of lung cancer recurrence

At the beginning of the 21st century, the World Health Organization announced the incidence of different types of lung cancer. The highest incidence was lung adenocarcinoma, about 31.5%, and squamous cell carcinoma ranked second, with an incidence of about 29.4%. Surgery is still the first choice for lung cancer treatment, and radical surgery is still the only possible way to cure lung cancer. In recent years, with the development of surgical operations, the number of patients undergoing lung cancer surgery has increased significantly, but the incidence of postoperative recurrence or metastasis is still high. So how do you determine whether lung cancer has recurred or metastasized?

The recurrence and metastasis of lung cancer are two different concepts. The former refers to the clinical cure of lung cancer through surgery, radiotherapy, chemotherapy and other means, and the discovery of new cancer tissue in the local lesion during follow-up examination. Metastasis refers to the spread of lung cancer to other parts of the body through various pathways. Metastasis can be the situation at the time of initial diagnosis or the situation that appears during follow-up examination after treatment. The common point between the two is that the pathological types of recurrent cancer and metastatic cancer are the same as those of the primary cancer.

If it is distant metastasis or recurrence, another important symptom is pain.

1. Bone pain: The ribs, lumbar spine, ilium, and femur are common recurrence sites. Pain is the most common symptom of bone metastasis. Sometimes there may be no pain and a fracture may occur directly.

2. Low back pain: The kidneys are also one of the favorite places for lung cancer to "make a comeback". Sometimes there may not be low back pain. Hematuria and abnormal renal function may also be suggestive signs.

3. Pain in the liver area: This symptom may occur when the liver metastasizes. If the pain is obvious, the patient needs to undergo a B-ultrasound examination. Combined with the results of liver function tests, it can help you initially understand whether there are any abnormalities in the liver.

4. Headache: On average, 10 out of 100 patients may have recurrences in the brain or spinal cord, with headache being the most common symptom. Other symptoms such as nausea and vomiting are also common. Other symptoms such as epilepsy, hemiplegia, unsteady walking, aphasia (sudden inability to speak), and fainting may also occur.

In clinical practice, Hecun Malt Selenium Capsules are used in combination with cancer patients. Selenium is known as the "king of anti-cancer". In September 2003, the US Food and Drug Administration (FDA) recognized selenium as a cancer inhibitor. This is the official medical statement of the US government that selenium can inhibit cancer. Some scientists have supplemented cancer patients with selenium for a long time, which has reduced the mortality rate of cancer patients by 50%. A large number of studies have shown that selenium is a powerful tumor inhibitor that can inhibit the growth of cancer cells and block the energy supply of cancer cells. At present, many scholars believe that selenium is not only effective in cancer prevention, but also can be used as a chemotherapy adjuvant to reduce the toxic side effects of chemotherapy drugs and increase drug tolerance.

The level of blood selenium is also related to the recurrence rate, spread, patient survival time and prognosis of cancer. For patients with higher blood selenium levels, the tumor may be limited to the primary site, the possibility of distant metastasis is lower, the recurrence rate may be lower, and the prognosis may be better. On the contrary, patients with significantly reduced blood selenium are more likely to have distant metastasis, high malignancy and short survival. The selenium content in cancer patients is lower than that in normal people. Hecun Malt Selenium Capsules have a high selenium content and are suitable for cancer patients.

Impact on recurrence and metastasis after radical surgery for lung cancer: For patients who have undergone radical surgery for lung adenocarcinoma, postoperative adjuvant therapy is now the main measure to improve the prognosis of tumor patients. Currently, postoperative adjuvant chemotherapy can improve the survival rate of patients undergoing surgery for stage II and III lung cancer, improve the prognosis, and has a definite effect, which has been unanimously recognized. In 2007, a study by the Cancer Research Center of the United States and Canada proposed guidelines for the treatment of non-small cell lung cancer after radical surgery. It is recommended that patients with stage IIA~IIIA who have undergone radical surgery be routinely given postoperative adjuvant platinum-containing chemotherapy.